Woodline Partners LP Increases Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Woodline Partners LP grew its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 23.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 221,102 shares of the company's stock after acquiring an additional 41,287 shares during the quarter. Woodline Partners LP owned about 0.77% of Krystal Biotech worth $34,638,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. FMR LLC raised its stake in Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after acquiring an additional 21,133 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after purchasing an additional 28,707 shares in the last quarter. Avoro Capital Advisors LLC increased its position in shares of Krystal Biotech by 0.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after purchasing an additional 6,600 shares in the last quarter. Hood River Capital Management LLC boosted its position in shares of Krystal Biotech by 2.1% in the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after purchasing an additional 10,622 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after purchasing an additional 71,200 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insider Buying and Selling

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68% decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

KRYS has been the subject of a number of research reports. Jefferies Financial Group began coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. Citigroup cut their target price on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a report on Friday, May 16th. Chardan Capital reiterated a "buy" rating and set a $219.00 price target on shares of Krystal Biotech in a research note on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $211.13.

Krystal Biotech Price Performance

Shares of KRYS stock traded down $0.24 during mid-day trading on Monday, hitting $125.05. The stock had a trading volume of 298,645 shares, compared to its average volume of 308,069. The firm has a market cap of $3.61 billion, a PE ratio of 41.82 and a beta of 0.79. The company's 50-day simple moving average is $161.34 and its 200-day simple moving average is $166.79. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. On average, analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).